Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price was down 0.3% during trading on Monday . The company traded as low as $26.61 and last traded at $26.63. Approximately 10,115,846 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 37,457,648 shares. The stock had previously closed at $26.72.
Analyst Ratings Changes
PFE has been the topic of a number of research analyst reports. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. UBS Group boosted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Barclays boosted their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.
Pfizer Trading Down 1.6 %
The stock has a 50-day moving average price of $28.89 and a two-hundred day moving average price of $28.67. The stock has a market capitalization of $149.04 billion, a PE ratio of 35.54, a PEG ratio of 0.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 1.00.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.
Pfizer Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.39%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.
Insider Buying and Selling
In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by insiders.
Institutional Trading of Pfizer
Large investors have recently made changes to their positions in the stock. German American Bancorp Inc. grew its stake in Pfizer by 9.6% in the 3rd quarter. German American Bancorp Inc. now owns 141,435 shares of the biopharmaceutical company’s stock worth $4,093,000 after acquiring an additional 12,423 shares in the last quarter. America First Investment Advisors LLC boosted its holdings in shares of Pfizer by 5.9% in the third quarter. America First Investment Advisors LLC now owns 650,254 shares of the biopharmaceutical company’s stock valued at $18,818,000 after purchasing an additional 35,978 shares during the period. Cypress Capital Group grew its stake in Pfizer by 2.7% in the third quarter. Cypress Capital Group now owns 121,314 shares of the biopharmaceutical company’s stock worth $3,511,000 after purchasing an additional 3,196 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in Pfizer during the 3rd quarter worth $1,319,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Pfizer by 164.2% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company’s stock valued at $211,737,000 after purchasing an additional 4,546,809 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.